Long-term treatment with haloperidol affects neuropeptide S and NPSR mRNA levels in the rat brain.

Acta Neuropsychiatr 2016 Apr 15;28(2):110-6. Epub 2015 Oct 15.

1Department of Histology,School of Medicine in Katowice,Medical University of Silesia,Katowice,Poland.

Objective: The brainstem-derived neuropeptide S (NPS) has a multidirectional regulatory activity, especially as a potent anxiolytic factor. Accumulating data suggests that neuroleptics affect peptidergic signalling in various brain structures. However, there is no information regarding the influence of haloperidol on NPS and NPS receptor (NPSR) expression.

Methods: We assessed NPS and NPSR mRNA levels in brains of rats treated with haloperidol using quantitative real-time polymerase chain reaction.

Results: Chronic haloperidol treatment (4 weeks) led to a striking upregulation of NPS and NPSR expression in the rat brainstem. Conversely, the NPSR mRNA expression was decreased in the hippocampus and striatum.

Conclusions: This stark increase of NPS in response to haloperidol treatment supports the hypothesis that this neuropeptide is involved in the dopamine-dependent anxiolytic actions of neuroleptics and possibly also in the pathophysiology of mental disorders. Furthermore, our findings underline the complex nature of potential interactions between dopamine receptors and brain peptidergic pathways, which has potential clinical applications.

Download full-text PDF

Source
https://www.cambridge.org/core/product/identifier/S092427081
Publisher Site
http://dx.doi.org/10.1017/neu.2015.56DOI Listing
April 2016
8 Reads

Publication Analysis

Top Keywords

npsr mrna
12
mrna levels
8
haloperidol treatment
8
nps npsr
8
nps
6
haloperidol
5
npsr
5
polymerase chain
4
disorders findings
4
real-time polymerase
4
quantitative real-time
4
chain reactionresults
4
mental disorders
4
chronic haloperidol
4
reactionresults chronic
4
findings underline
4
treatment weeks
4
pathophysiology mental
4
rats treated
4
expressionmethods assessed
4

References

(Supplied by CrossRef)
S-16924 [(R)-2-[1-[2-(2,3-dihydro-benzo[1,4]dioxin-5-yloxy)-ethyl]- pyrrolidin-3yl]-1-(4-fluorophenyl)-ethanone], a novel, potential antipsychotic with marked serotonin1A agonist properties: III. Anxiolytic actions in comparison with clozapine and haloperidol
Millan et al.
J Pharmacol Exp Ther 1999
Neuroleptics affect neuropeptide S and NPSR mRNA levels in the rat brain
PaƂasz et al.
J Mol Neurosci 2015

Similar Publications